Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors

Breast Cancer Research and Treatment

Volumn 104, Issue 3, 2007, Pages 321-329

  Graves, Kristi D ^a   Peshkin, Beth N ^a   Halbert, Chanita H ^b   DeMarco, Tiffani A ^a   Isaacs, Claudine ^a   Schwartz, Marc D ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BRCA1 2; Breast cancer survivors; Contralateral prophylactic mastectomy; Distress outcomes; Genetic testing; Psychosocial predictors

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; ETHNICITY; FEMALE; GENE MUTATION; GENETIC COUNSELING; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; ONCOGENE; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MASTECTOMY; MODELS, GENETIC; MUTATION; ODDS RATIO; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547741530     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9423-5     Document Type: Article

References (38)

1. Fisher ER, Fisher B, Sass R et al (1984) Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). XI. Bilateral breast cancer. Cancer 54:3002-3011
2. Metcalfe K, Lynch HT, Ghadirian P et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328-2335
3. Verhoog LC, Brekelmans CT, Seynaeve C et al (2000) Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 83:384-386
4. Helzlsouer KJ (2005) Contralateral prophylactic mastectomy: quantifying benefits and weighing the harms. J Clin Oncol 23:4251-4253
5. Herrinton LJ, Barlow WE, Yu O et al (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23:4275-4286
6. McDonnell SK, Schaid DJ, Myers JL et al (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19:3938-3943
7. Peralta EA, Ellenhorn JD, Wagman LD et al (2000) Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180:439-445
8. van Sprundel TC, Schmidt MK, Rookus MA et al (2005) Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93:287-292
9. Schwartz MD, Lerman C, Brogan B et al (2004) Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22:1823-1829
10. Weitzel JN, McCaffrey SM, Nedelcu R et al (2003) Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 138:1323-1328
11. Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M et al (2003) Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 21:1675-1681
12. Lynch HT, Snyder C, Lynch JF et al (2006) Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. Cancer Genet Cytogenet 165:91-97
13. Schwartz MD, Kaufman E, Peshkin BN et al (2003) Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 21:4034-4041
14. Diefenbach MA, Miller SM, Daly MB (1999) Specific worry about breast cancer predicts mammography use in women at risk for breast and ovarian cancer. Health Psychol 18:532-536
15. Schwartz MD, Lerman C, Miller SM et al (1995) Coping disposition, perceived risk, and psychological distress among women at increased risk for ovarian cancer. Health Psychol 14:232-235
16. van Oostrom I, Meijers-Heijboer H, Lodder LN et al (2003) Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol 21:3867-3874
17. Frost MH, Schaid DJ, Sellers TA et al (2000) Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284:319-324
18. Geiger AM, West CN, Nekhlyudov L et al (2006) Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol 24:1350-1356
19. Tercyak KP, Peshkin BN, Brogan BM et al (2006) Quality of life following contralateral prophylactic mastectomy in newly diagnosed high risk breast cancer patients who underwent BRCA1/BRCA2 gene testing (under review)
20. Couch FJ, DeShano ML, Blackwood MA et al (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409-1415
21. Frank TS, Manley SA, Olopade OI et al (1998) Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16:2417-2425
22. Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145-158
23. Robson M, Dabney MK, Rosenthal G et al (1997) Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test 1:47-51
24. Halbert CH, Wenzel L, Lerman C et al (2004) Predictors of participation in psychosocial telephone counseling following genetic testing for BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 13:875-881
25. Schwartz MD, Peshkin BN, Hughes C et al (2002) Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 20:514-520
26. Peshkin BN, Schwartz MD, Isaacs C et al (2002) Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 11:1115-1118
27. Horowitz M, Wilner N, Alvarez W (1979) Impact of Event Scale: a measure of subjective stress. Psychosom Med 41:209-218
28. Derogatis LR (1977) SCL-90: administration, scoring, and procedures manual-I for the R (revised) version. Johns Hopkins University School of Medicine, Clinical Psychometrics Research, Baltimore
29. Lerman C, Hughes C, Croyle RT et al (2000) Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31:75-80
30. Phillips KA, Jenkins MA, Lindeman GJ et al (2006) Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clin Genet 70:198-206
31. Scheuer L, Kauff N, Robson M et al (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260-1268
32. Lodder LN, Frets PG, Trijsburg RW et al (2002) One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 73:97-112
33. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT et al (2000) Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355:2015-2020
34. Julian-Reynier CM, Bouchard LJ, Evans DG et al (2001) Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 92:959-968
35. Frost MH, Slezak JM, Tran NV et al (2005) Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 23:7849-7856
36. Nekhlyudov L, Bower M, Herrinton LJ et al (2005) Women's decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst Monogr 35:55-60
37. Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615
38. Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622